EMERALD ADVISERS, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 56 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2013. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
EMERALD ADVISERS, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2019$8,489,000
-27.6%
127,927
-13.2%
0.40%
-15.9%
Q2 2019$11,729,000
-13.2%
147,409
+22.0%
0.47%
-14.4%
Q1 2019$13,515,000
+42.3%
120,820
-25.7%
0.55%
+50.3%
Q4 2017$9,497,000
+2.1%
162,560
+89.9%
0.37%
-7.8%
Q4 2016$9,301,000
-25.7%
85,603
+12.5%
0.40%
-28.7%
Q3 2016$12,522,000
+65.7%
76,079
+43.7%
0.56%
+53.0%
Q2 2016$7,555,000
+33.2%
52,950
+20.0%
0.36%
+31.9%
Q1 2016$5,671,000
-22.1%
44,139
-9.4%
0.28%
-19.8%
Q4 2015$7,280,000
-36.8%
48,742
-29.8%
0.34%
-42.8%
Q3 2015$11,510,000
-29.4%
69,398
+2.8%
0.60%
-22.7%
Q2 2015$16,294,000
-10.6%
67,504
-1.0%
0.78%
-15.0%
Q1 2015$18,217,000
+73.2%
68,180
+1.1%
0.91%
+63.8%
Q4 2014$10,517,000
+443.5%
67,415
+724.4%
0.56%
+385.2%
Q3 2014$1,935,000
-67.4%
8,177
-67.4%
0.12%
-65.7%
Q2 2014$5,942,000
-33.5%
25,113
-7.4%
0.34%
-33.4%
Q1 2014$8,942,000
-10.4%
27,113
-81.5%
0.50%
-6.9%
Q4 2013$9,980,000
-14.7%
146,167
-13.8%
0.54%
-18.3%
Q3 2013$11,704,000
+430.8%
169,543
+244.8%
0.66%
+393.3%
Q2 2013$2,205,00049,1750.13%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2013
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders